Kahira Pharmaceuticals and Chemical Industries Company has announced an impressive 25.6% increase in profits for the first quarter of the current fiscal year 2024, according to the financial indicators released today. This significant growth highlights the company’s robust performance and strategic market positioning.
For the period spanning from July to September 2024, Kahira Pharmaceuticals reported a net profit of EGP 74.34 million. This marks a substantial rise from the EGP 59.17 million recorded during the same quarter of the previous financial year. The company’s strong financial performance underscores its ability to navigate market challenges and capitalize on growth opportunities.
The company’s sales also saw a noteworthy increase, rising to EGP 420.77 million in the first quarter, compared to EGP 334.17 million in the comparative period last year. This surge in sales reflects Kahira Pharmaceuticals’ successful efforts in expanding its market reach and enhancing its product offerings.
In a broader context, Kahira Pharmaceuticals recorded a net profit of EGP 246.13 million for the fiscal year from July 2023 to June 2024. This is a significant improvement compared to the EGP 97.09 million profit in the preceding financial year, signaling strong and sustained growth.
